Breast Cancer,Other Cancers MAINTAIN Trial: Fulvestrant or Exemestane +/- Ribociclib After Progression on CDK 4/6I for HR+, HER2- MBC May 10, 2023
Breast Cancer,Other Cancers MINDACT Trial: Patients with Ultralow-Risk 70-Gene Signature Show Positive Outcome May 10, 2023
Breast Cancer,Other Cancers Node-Positive Breast Cancer Patients Can Use the 21-Gene Assay to Determine Chemo Benefit, Study Finds May 10, 2023
Breast Cancer,Other Cancers ALP + ET in PIK3CA-mutated HR+/HER2- ABC: Baseline analysis and PFS by prior CDK4/6i duration (BYLieve) May 10, 2023
Breast Cancer,Other Cancers Alpelisib + Fulvestrant in HR+/HER2- Advanced Breast Cancer: Biomarker Analyses From SOLAR-1 NGS Study May 10, 2023
Breast Cancer,Other Cancers The Power of PADA-1: Palbociclib and Circulating Tumor DNA in Detecting ESR1 Mutations May 10, 2023
Breast Cancer,Other Cancers Molecular Plasticity of Luminal Breast Cancer and Response to Palbociclib Treatment May 10, 2023
Breast Cancer,Other Cancers Effect of BMI on Treatment and Outcomes in Early HR+/HER2- BC With or Without Palbociclib May 08, 2023
